menu search

PRCT / Procept: Leveraging A Novel Water-Based System For Enlarged Prostate Treatment

Procept: Leveraging A Novel Water-Based System For Enlarged Prostate Treatment
PROCEPT has developed a system to treat enlarged prostate disease, and is banking on competitive advantage over legacy treatment options. The common disease, more prevalent as populations grow older, provides the company with a large TAM to drive growth. Read More
Posted: May 26 2022, 01:37
Author Name: Seeking Alpha
Views: 111937

PRCT News  

PROCEPT BioRobotics Corporation (PRCT) Q3 2023 Earnings Call Transcript

By Seeking Alpha
November 2, 2023

PROCEPT BioRobotics Corporation (PRCT) Q3 2023 Earnings Call Transcript

PROCEPT BioRobotics Corporation (PRCT) Q3 2023 Earnings Call Transcript more_horizontal

Procept BioRobotics: Adding Value Through Robust Unit Economics, Reiterate Buy

By Seeking Alpha
August 10, 2023

Procept BioRobotics: Adding Value Through Robust Unit Economics, Reiterate Buy

PRCT's aquablation therapy has shown strong growth, with revenues of $57.5mm in Q2 FY'23. The company's economic levers include new system placements, more_horizontal

PROCEPT BioRobotics Corporation (PRCT) Reports Q2 Loss, Tops Revenue Estimates

By Zacks Investment Research
July 27, 2023

PROCEPT BioRobotics Corporation (PRCT) Reports Q2 Loss, Tops Revenue Estimates

PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.57. This more_horizontal

PROCEPT BioRobotics to Report Second Quarter 2023 Financial Results on July 27, 2023

By GlobeNewsWire
July 11, 2023

PROCEPT BioRobotics to Report Second Quarter 2023 Financial Results on July 27, 2023

REDWOOD CITY, Calif., July 11, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics comp more_horizontal

Procept BioRobotics: Adding For 2023 Rebound

By Seeking Alpha
May 30, 2023

Procept BioRobotics: Adding For 2023 Rebound

Procept had weak results on adding fewer than expected Aquabeam devices in Q1 of 2023, leading to a fall in the shares. Procept has strong potential i more_horizontal

PROCEPT BioRobotics Corporation (PRCT) Q1 2023 Earnings Call Transcript

By Seeking Alpha
April 30, 2023

PROCEPT BioRobotics Corporation (PRCT) Q1 2023 Earnings Call Transcript

Start Time: 08:00 January 1, 0000 8:56 AM ET PROCEPT BioRobotics Corporation (NASDAQ:PRCT ) Q1 2023 Earnings Conference Call April 27, 2023, 08:00 AM more_horizontal

PROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue Estimates

By Zacks Investment Research
April 27, 2023

PROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue Estimates

PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.59. This more_horizontal

PROCEPT BioRobotics to Report First Quarter 2023 Financial Results on April 27, 2023 and Present at the Bank of America 2023 Health Care Conference in Las Vegas

By GlobeNewsWire
April 5, 2023

PROCEPT BioRobotics to Report First Quarter 2023 Financial Results on April 27, 2023 and Present at the Bank of America 2023 Health Care Conference in Las Vegas

REDWOOD CITY, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics com more_horizontal


Search within

Pages Search Results: